Background: We analyzed whether co-occurring mutations influence the outcome of systemic therapy in ALK-rearranged nonsmall-cell lung cancer (NSCLC).
Introduction ALK-positive non-small-cell lung cancer (NSCLC) is characterized by ALK gene rearrangements and an association with acinar histology, younger age and never-smoking status [1] . ALK rearrangements lead to constitutive activation of the encoded tyrosine kinase and downstream transforming signaling pathways [2] . Crizotinib, the first approved ALK-inhibitor, is superior to chemotherapy regarding overall response rate, progression-free survival (PFS), toxicity profile [3, 4] and overall survival (OS) [5] [6] [7] . Next-generation inhibitors with activity against ALK resistance mutations are in clinical evaluation and partly already approved [8] [9] [10] [11] . An impressive OS was reported for sequential ALK-inhibitor therapy ranging from 45 to 89.6 months [12] [13] [14] .
There are considerable differences in the clinical course of ALK-positive NSCLC patients treated with chemotherapy or ALK inhibitors [3, 4, 15, 16] . Genetic heterogeneity of ALK-positive tumors could explain this observation. We have molecularly analyzed 216 ALK-positive patients with advanced disease and hypothesized that co-occurring mutations might underlie these differences.
Patients and methods

Patients and samples
The study was carried out within the Network Genomic Medicine [17] , which offers centralized molecular diagnostics at the University Hospital of Cologne for patients with lung cancer from 300 participating partners. The study was conducted in concordance with local ethical guidelines. Patients were treated with crizotinib, ceritinib, alectinib or brigatinib according to national guidelines or within clinical trials [PROFILE1005 (NCT00932451); PROFILE1007 (NCT00932893); CLDK378X2101 (NCT-1283516); ASCEND-5 (NCT01828112); ALTA (AP26113) (NCT02094573); ACCALIA (NCT01801111)].
Fluorescence in situ hybridization ALK, RET and ROS1 rearrangements were diagnosed using break-apart fluorescence in situ hybridization (FISH) [17] . MET and ERBB2 were tested for amplification as reported [18] . Details are described in supplementary Table S1 , available at Annals of Oncology online.
Next-generation sequencing
Samples were analyzed with either a validated gene panel using AmpliSeq chemistry (Thermofisher, LUN3) comprising 102 amplicons of 14 different genes or a validated gene panel using GeneRead chemistry (Qiagen, LUN4), comprising 17 genes [19] . Details are described in supplementary  Table S6 , available at Annals of Oncology online. ALK variants were determined using the Archer V R FusionPlex V R Lung Kit and Archer Molecular Barcode (MBC) Adapters (both for Illumina) according to the manufacturer's instructions.
Programmed death-ligand 1 immunohistochemistry
Programmed death-ligand 1 (PD-L1) immunohistochemistry was carried out on the Leica Bond platform using primary antibody clone 28-8 (Abcam, Cambridge, UK). Interpretation was done according to the Dako PD-L1 22C3 pharmDx guidelines, results were reported based on an integrated proportion score [20, 21] .
Data collection
The Network Genomic Medicine database covers molecular diagnostics and basic demographic and clinical data. For treatment outcome medical records were reviewed. PFS was determined based on RECIST v1.1. Time of death was determined either via medical records or requests to local registry offices. OS was defined as the time from first diagnosis of stage IIIB/IV until death. For subjects alive at completion of this analysis, time to death was censored at the time of last contact.
Statistical analyses
Statistical analyses were carried out using IBM SPSS software 24 (IBM, Armonk, NY). Chi-squared and two-sided Fischer's exact tests were used for analyzing qualitative variable characteristics in different groups. The Kaplan-Meier estimator was used to calculate OS and PFS. Two-sided log-rank tests were applied to compare differences between treatment groups. Cox proportional hazards model was used to adjust for potential confounders. P values <0.05 were considered statistically significant.
Results
Patient characteristics
Between January 2011 and December 2016, 423 ALK-positive patients were identified using FISH. From 289 patients with written informed consent, 53 had no stage IIIB/IV and 20 were lost to follow up. About 216 patients were eligible ( Figure 1A Figure 1A ).
For 175 patients (81%) follow-up data for OS were available including 7 patients (3.2%) treated with best supportive care. Thus, 168 patients (77.8%) were subdivided ( Figure 1B ) into cohort A including 42 patients (19.4%) treated with chemotherapy only, cohort B including 71 patients (33%) with crizotinib and chemotherapy, cohort C including 18 patients (8.3%) with firstline crizotinib and cohort D including 37 patients (17.1%) with ceritinib after crizotinib with or without chemotherapy. Supplementary Figure S2 , available at Annals of Oncology online shows treatment sequences in cohort D.
From 41 patients (19%, cohort Z) no complete therapy data until death or final follow-up were available including 5 patients treated with alectinib and 2 with brigatinib.
Co-occurring mutations, PD-L1 status and ALK variants
Mutations in TP53 were the most frequent co-occurring mutations with 23.8% (34/143) of the tested patients. Among 36 TP53 mutations 34 were classified as nonfunctional [22] , 2 were of unknown functional significance (supplementary Table S5 , available at Annals of Oncology online). All other co-alterations occurred rarely with frequencies between 0.6% for BRAF (1/171), 0.6% for KRAS (1/174) and 3.6% (4/112) for low-level MET amplification (Figure 2A and supplementary Table S4 , available at Annals of Oncology online). Four patients showed more than 1 co-occurring alteration (supplementary Figure S1 , available at Annals of Oncology online).
PD-L1 expression of tumor cells was assessed in 34 patients (supplementary Table S4 , available at Annals of Oncology online). In eight patients (23.5%) the PD-L1 score [21] In 18 of 34 patients (53%) ALK variant 1 was found, in 14 patients (41%) variant 3a/b and in 2 patients (6%) variant 2 (supplementary Table S8 , available at Annals of Oncology online).
PFS dependent on therapy and TP53 mutations PFS was assessed in 157 patients with first-line chemotherapy (140 patients cohorts A-D plus 17 patients cohort Z, see Figure 1B ), thereof 149 patients with platinum-based chemotherapy (109 resp. 103 PD at data cutoff), for crizotinib after chemotherapy in 112 patients (cohorts B-D and partly Z; 73 PD at data cutoff), for TP53 mutations were a negative prognostic factor for PFS regardless of systemic therapy. Median PFS with first-line chemotherapy was 2.6 months (95% CI: 1.3-4.1) with mutated TP53 (n ¼ 27) and 6.2 months (95% CI: 1.8-10.5) with TP53 wt (n ¼ 75) (P ¼ 0.021). For crizotinib first-line median PFS was 5.5 months only (95% CI: 0.0-10.9) with mutated TP53 (n ¼ 3) versus 29.9 months (95% CI: 0.0-63.9) with TP53 wt (n ¼ 15) (P ¼ 0.007). Similarly, for crizotinib after chemotherapy median PFS was 5.0 months (95% CI: 2.3-7.8) with mutated TP53 (n ¼ 19) versus 14.0 months (95% CI: 9.5-18.6) with TP53 wt (n ¼ 56) (P ¼ 0.004). Regardless of treatment line, TP53 mutation status segregated the median PFS of crizotinib-treated patients in an unfavorable TP53-mutated group [n ¼ 22; 5.0 months (95% CI: 2.9-7.2)] and a favorable TP53 wt group (n ¼ 71; 14.0 months (95% CI: 8.0-20.1); P < 0.001]. Also, median PFS with next-generation ALK inhibitors after crizotinib was worse in patients with mutated TP53 [n ¼ 11; 5.4 months (95% CI: 0.1-10.7)] compared with TP53 wt [n ¼ 22, 9.9 months (95% CI: 6.4-13.5); P ¼ 0.039]. In total, PFS of TP53 co-mutated patients was 3.9 months [n ¼ 60 (95% CI: 2.4-5.6)] and 10.3 months in TP53 wt patients [n ¼ 168 (95% CI: 8.6-12.0)] regardless of treatment (P < 0.001) ( Figure 3A and supplementary Table S2 , available at Annals of Oncology online).
The ALK variant 3a/b subgroup (cohorts A-D, n ¼ 20) showed a nonsignificant trend toward better PFS with 11.9 months (95% CI: 0.9-23.1) versus variant 1 (n ¼ 31) with 7.9 months (95% CI: 1.6-14.4) (P ¼ 0.285). TP53 mutations were negative predictive in both variant subgroups (n ¼ 30; P ¼ 0.001) with a strong trend in variant 1 [2.6 month (95% CI: 0.0-10.9) versus 15.9 months (95% CI: 1.4-30.6); P ¼ 0.068] and reaching statistical significance in variant 3a/b (P ¼ 0.022). Cox regression suggested a negative impact of TP53 mutations on PFS regardless of ALK variants (n ¼ 30; P ¼ 0.002) (supplementary Tables S8 and S9 , available at Annals of Oncology online).
OS dependent on therapy and TP53 mutations OS was assessed for 168 patients in cohorts A-D ( Figure 1B ). Median OS with chemotherapy only (cohort A, n ¼ 42, 31 events at data cutoff) was with 9.0 months (95% CI: 5.0-12.9) inferior to all other cohorts treated with ALK inhibitors: cohort B (n ¼ 71, 32 events) 31.0 months (95% CI: 0.4-61.6); P < 0.001, cohort C (n ¼ 18, 2 events) median not reached (P ¼ 0.001), cohort D (n ¼ 37, 20 events) 45.0 months (95% CI: 32.3-57.7); P < 0.001. OS of patients treated with crizotinib starting from the first dose (n ¼ 89; cohorts B þ C) was 17.0 months (95% CI: 10.6-23.9). TP53 mutations were a strong negative predictor for median OS in all cohorts. Median OS of mutated TP53 patients (n ¼ 34) was 15.0 months (95% CI: 5.0-24.9) compared with 50.0 months (95% CI: 22.9-77.1) for TP53 wt patients (n ¼ 109) (P ¼ 0.002). With chemotherapy only (cohort A), the median OS in TP53-mutated patients (n ¼ 7) was 2.0 months (95% CI: 0.0-4.6) compared with 9.0 months (95% CI: 6.1-11.9) in TP53 wt patients (n ¼ 15) (P ¼ 0.035). For crizotinib-treated patients (cohorts B þ C), OS for TP53-mutated patients (n ¼ 13) was 17.0 months (95% CI: 6.7-27.3) compared with TP53 wt patients (n ¼ 50) for whom the median OS was not reached (P ¼ 0.049). Also for patients treated with ceritinib after crizotinib (cohort D), a striking difference in OS was observed with 7.0 months only (95% CI: not reached) for TP53 mutated patients (n ¼ 4) and 50.0 months (95% CI: not reached) (P ¼ 0.001) for TP53 wt patients (n ¼ 20).
Within the TP53-mutated patient cohort, median OS with chemotherapy only (n ¼ 7) was 2.0 months (95% CI: 0.0-4.6) and thus inferior to ALK-inhibitor treatment (n ¼ 15) with 17.0 months (95% CI: 4.6-29.4) (P ¼ 0.025). For TP53 wt patients treated with chemotherapy only (n ¼ 15), the median OS was 9.0 months (95% CI: 6.1-11.9) compared with a median OS of 50.0 months (95% CI: 22.3-77.7) (P < 0.001) for TP53 wt patients treated with ALK inhibitors with or without chemotherapy (n ¼ 54) (Figure 3B and supplementary Table S3 , available at Annals of Oncology online).
In univariate analysis including age, sex, smoking history, current smoker status, Eastern Cooperative Oncology Group (ECOG) performance status, number of brain metastases, number of treatment lines before crizotinib or ceritinib and TP53 mutation status only current smoker status and TP53 mutations were significant negative prognostic factors for OS (P ¼ 0.016 and P ¼ 0.002, respectively). In multivariate Cox regression analysis only TP53 mutation remained an independent negative prognostic factor (P ¼ 0.004) (supplementary Table S7 , available at Annals of Oncology online).
Patients with ALK variant 3a/b (n ¼ 14) had a nonsignificant better OS of 50 months (95% CI: 0.0-108.9) compared with variant 1 (n ¼ 18) with 29.0 months (95% CI: 9.4-48.6) (P ¼ 0.815). TP53 mutations were prognostic negative in both variant subgroups reaching statistical significance in variant 1 (P ¼ 0.032) (supplementary Table S8 , available at Annals of Oncology online).
Discussion
We show that in ALK-positive NSCLC TP53 mutations separate roughly one quarter of patients with a substantially worse outcome. PFS and OS were inferior compared with TP53 wt patients treated with chemotherapy and ALK inhibitors.
TP53 alterations may damage tumor suppressor functions as loss of function mutations or trigger inhibition of apoptosis and genomic instability as gain of function mutations [23] . Thus, a negative prognostic impact of TP53 mutations in cancer has been postulated and preclinical observations support this hypothesis [24] . While in unselected NSCLC such a negative prognostic impact has not been proven unequivocally [25] [26] [27] [28] [29] , it has been reported in numerous reports for EGFR-mutated NSCLC treated with EGFR inhibitors. These results, however, only partly reached statistical significance [30] [31] [32] [33] [34] . In ALK-positive lung cancer, TP53 mutations so far have not been described as significant negative prognostic factors.
The outcome in our treatment-related subgroups independently of TP53 status confirmed what has been described in clinical trials [3, 4, 16] and registry analyses [6, 7, [12] [13] [14] 35] : superiority of ALK inhibitors over chemotherapy in terms of PFS and superiority of sequential ALK-inhibitor therapy compared with crizotinib monotherapy in terms of OS. Our results additionally show that TP53 mutations represent the by far most frequent cooccurring mutations in ALK-positive NSCLC. By comparison, we found other co-mutations with a frequency of below 4% only; among them rarely those with actionable mutations like BRAFV600, high-level MET amplification or activating KRAS mutation.
Most important, our results suggest that about one-fourth of ALK-positive patients do not substantially benefit from recent progress of targeted therapy. As a limitation, concerning the use of next-generation ALK inhibitors statistically valid OS data could be assessed only for ceritinib. Future studies will have to prove, whether our findings can be confirmed for other nextgeneration ALK inhibitors.
In many cancer types, TP53 mutations were shown to be associated with higher genetic instability [24] . Accordingly, we could recently show that early TP53 mutations can lead to chromosomal instability in ALK-positive NSCLC [36] . It is tempting to speculate that a higher mutational burden might lead to a better efficacy of immune checkpoint inhibitors. Of note, the proportion of patients with PD-L1 positive tumor cells is enriched in our TP53-mutated group, although the number of patients is rather small.
Recently, in post ALK-inhibitor treatment biopsies it was shown that the type of ALK variant influences the development of ALK-inhibitor resistance mutations. In particular, EML4-ALK variant 3 was correlated with the development of ALK G1202R resistance mutation and a better PFS under treatment with the third-generation ALK-inhibitor lorlatinib, but not with first-and second-generation ALK inhibitors [37] . Similarly, in our pretreatment biopsies we saw a nearly equal distribution between ALK variants 1 and 3a/b and no significant influence of first-and second-generation ALK inhibitors on PFS. TP53 mutations were negative prognostic in terms of PFS and OS in both variant subgroups. Based on the low patient number, which limits our conclusions, significance was only partly reached. It remains to be elucidated whether TP53 mutation status and ALK variant status are independent prognostic factors.
In summary, we here describe TP53 mutations as the first pretreatment biomarker in ALK-positive NSCLC identifying patients with a substantially worse outcome from therapy. In future clinical trials stratification of this patient subgroup should be considered and new treatment strategies investigated to improve the outcome of ALK/TP53 co-mutated patients.
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